SMAD2 and gastric cancer: Initially, the study noted a reduction in miR-6809-3p levels in GC tissues and cell lines, suppressing GC cell migration and proliferation, enhancement of apoptosis, and influencing EMT and the TGF-β1/SMAD2/3 pathway.